about
Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationSingle-step selection of drug resistant Acinetobacter baylyi ADP1 mutants reveals a functional redundancy in the recruitment of multidrug efflux systemsInfections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation.The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection.Acinetobacter baumannii outer membrane vesicles elicit a potent innate immune response via membrane proteins.Current strategies for the prevention and management of central line-associated bloodstream infections.Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.Acinetobacter baumannii Septicemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation.Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens.Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.Nosocomial Acinetobacter baumannii Infections and Changing Antibiotic Resistance.Validation of a novel murine wound model of Acinetobacter baumannii infection.Multidrug-resistant Gram-negative infections: the use of colistin.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.The enhanced permeability retention effect: a new paradigm for drug targeting in infection.Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000-2015).Epidemiology of multidrug-resistant Acinetobacter baumannii strains in Iran: a systematic review and meta-analysis.Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii.Antibiotic resistance and carriage class 1 and 2 integrons in clinical isolates of Acinetobacter baumannii from Tehran, Iran.Clinical analysis of pulmonary infection in hemodialysis patients.Adaptation to Potassium-Limitation Is Essential for Acinetobacter baumannii Pneumonia Pathogenesis.High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Detection of class 1 integron in Acinetobacter baumannii isolates collected from nine hospitals in Turkey.In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli.AtfA, a new factor in global regulation of transcription in Acinetobacter spp.The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study.Identifying Risk Factors for Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii in a Neonatal Intensive Care Unit.In vitro effects of N-acetylcysteine alone and combined with tigecycline on planktonic cells and biofilms of Acinetobacter baumannii.Antibiotic treatment modulates protein components of cytotoxic outer membrane vesicles of multidrug-resistant clinical strain, DU202
P2860
Q24615937-5E7DDDA2-C9AE-4335-9502-506745836FC1Q28486038-C1066F1E-D3A3-439C-9FA1-9D332268E1A8Q33892585-B9F3CCCA-D678-46AE-A6F9-C331459F463AQ34511617-08CA8FD7-B22B-4019-BD61-7DDA5C972380Q34972141-F4849F3B-FFAA-4E4C-92BE-F543862BAF3FQ35026591-3FE19C8B-77CB-44C5-B33E-672CDA9839F5Q35297743-4DFDF714-0283-4D8F-A6AC-8E30A6778DF4Q36364023-FCE9EF0B-39A7-47EF-AA97-368466FF699EQ36417501-55A6D46C-93AF-4831-A369-94699963C336Q36505406-483AB0F6-2A6E-411C-BDD3-767FAEEF618FQ37287693-C992895D-3186-406B-9C18-F32240CA3C49Q37382724-2A55F3D2-0DC7-4528-895A-6291BB6EC88AQ37643643-29CD92A8-3464-4A67-85F3-F07B63A31B98Q37785545-42A55CDF-3F7C-4ECE-8D04-D09311798A4FQ37838117-CC5AF2F2-8191-467F-B71C-11B98DC54EB3Q37869910-A832FCC7-2F20-461A-A94B-AA14CBEF3777Q38051263-1EA5F16C-C5A7-48CC-8DED-BA0AB3A7708AQ38197844-BED9AF29-B2AE-418D-A130-A686B71F40B5Q38212031-B25C3D4E-0C43-4014-9843-19E3A8B7226EQ38672110-071716E1-C0BE-41FD-82BF-DCAF99DD2825Q38722054-8A937AE2-9F8C-4958-9340-4F8BC5DBCA7CQ39659392-1FC35392-A5C6-4845-8714-5BF9D0D5A062Q39865670-E2B9FD18-BD01-4041-B482-E16E724D2835Q40240848-6E03550B-89FC-47D1-8353-920BD3176118Q40421190-9E5F4962-9E17-411E-9F45-FA7D95BE1791Q41179174-CFE589A3-D0FB-4EED-8C23-FF735C9E5A77Q41561999-E47717DB-A78D-4B91-8428-F941ACEA199CQ41571185-421D9FBC-E2DE-4BF7-8DE8-2F36E438FC88Q41833657-B18617DE-02ED-4FFA-BE6C-BBA9B8E672C8Q41922309-B9DEB0AA-614A-474F-8AF8-F15A0A0F7454Q42285210-8540E5EB-1D6A-44F2-A463-9CA6472BA9E9Q44449024-D61A60FC-ECC3-423A-A648-D85DEF585863Q46863507-0952731F-DB79-450C-839E-56FDBE2C295EQ47744180-A626FD2E-14CD-4B50-BA7D-DDE46CEC61CEQ53689690-8C43E88D-6BFD-4823-AA1D-BCE4934A921CQ53692088-D586A5D1-380A-46D8-959C-C27C7F262720Q55266091-EDD7B504-C7D9-4114-BCC5-309742D41758Q57751819-A3ED8226-8618-4317-A6F0-9290943CA6A6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of Acinetobacter infections.
@en
type
label
Treatment of Acinetobacter infections.
@en
prefLabel
Treatment of Acinetobacter infections.
@en
P2860
P1476
Treatment of Acinetobacter infections.
@en
P2093
Argyris Michalopoulos
P2860
P304
P356
10.1517/14656561003596350
P407
P577
2010-04-01T00:00:00Z